Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?

F. Nichetti, F.S. Falvella, R. Miceli, S. Cheli, R. Gaetano, G. Fucà, G. Infante, A. Martinetti, C. Antoniotti, A. Falcone, M. Di Bartolomeo, C. Cremolini, F. de Braud, F. Pietrantonio

Research output: Contribution to journalArticle

Cite this